We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Proposes ‘Dedicated Biosimilar Unit’ for BsUFA II
FDA Proposes ‘Dedicated Biosimilar Unit’ for BsUFA II
In response to industry concerns about the FDA’s handling of biosimilar applications, the agency is looking to establish a dedicated biosimilar review unit as part of BsUFA reauthorizations.